Habitual, a healthcare company dedicated to empowering sustainable weight loss and long-lasting habit change, today announces a £1 million funding round with backing from Lexham Partners. Existing board member, Professor Sneh Khemka CBE, also joins as Chairman.
With more than half a million Brits being prescribed Wegovy and Mounjaro, the weight loss market is booming. The global market for weight loss medications is forecast to grow dramatically over the coming years to around £119bn.
Providing holistic weight loss solutions including GLP-1 medication, meal replacement shakes and soups, and personalised support, Habitual will use its recent funding to expand its pipeline of holistic ancillary products and services to cater to individuals on their weight loss journeys.
With over half a million people in the UK now using GLP-1 medications and the NHS funding weight loss programmes for patients with type 2 diabetes, it’s clear that we are in a transformational time for metabolic health. This funding allows us to accelerate the development of our holistic, science-backed solutions that go beyond just medication - ensuring that people have the long-term support they need to sustain real, lasting health improvements.
Napala Pratini, Founder & CEO
I am proud to be joining Habitual as Chairman at this pivotal moment. The company is helping thousands of people to lose weight in a responsible and sustained manner, and supporting the NHS to reverse type 2 diabetes in those most in need. After many years of an obesity crisis, we are now seeing the tide turning, and with the money raised we can help even more people up and down the country.
Professor Sneh Khemka CBE, Chairman
